Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
3상
완료
NCT03517449
| 대상 질환 | Endometrial Neoplasms |
|---|
| 임상 단계 | 3상 |
|---|
| 스폰서 | Eisai Inc. |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 827 명 |
|---|
| 중재(약물) | Pembrolizumab, Lenvatinib, Paclitaxel, Doxorubicin |
|---|
| 시작일 | 2018년 6월 11일 |
|---|
| 완료일 | 2022년 3월 1일 |
|---|
| 결과 공개일 | 2021년 11월 17일 |
|---|
요약
This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to receive either pembrolizumab and lenvatinib or treatment of physician's choice. The primary study hypothesis is that pembrolizumab in combination with lenvatinib prolongs progression free survival (PFS) and overall survival (OS) when compared to treatment of physician's choice.
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants
Up to approximately 27 months · Months
| Lenvatinib 20 mg + Pembrolizumab 200 mg | 6.6 ± 5.6 Months |
|---|
| Treatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel | 3.8 ± 3.6 Months |
|---|
| p-value | < 0.0001 |
|---|
| Hazard Ratio (HR) | 0.60 (95% CI 0.50–0.72) |
|---|
PFS Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on BICR in All-comer Participants
Up to approximately 27 months · Months
| Lenvatinib 20 mg + Pembrolizumab 200 mg | 7.2 ± 5.7 Months |
|---|
| Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel | 3.8 ± 3.6 Months |
|---|
| p-value | < 0.0001 |
|---|
| Hazard Ratio (HR) | 0.56 (95% CI 0.47–0.66) |
|---|
Overall Survival (OS) in pMMR Participants
Up to approximately 43 months · Months
| Lenvatinib 20 mg + Pembrolizumab 200 mg | 18.0 Months |
|---|
| Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel | 12.2 Months |
|---|
| p-value | < 0.0001 |
|---|
| Hazard Ratio (HR) | 0.70 (95% CI 0.58–0.83) |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.